513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Arrowhead Pharmaceuticals reported a fiscal 2024 net loss attributable to the company of $599.5 million, or $5.00 per diluted share, for the year ended September 30, 2024, compared with a loss of $205.3 million, or $1.92 per share, a year earlier. Revenue fell to $3.6 million from $240.7 million, while research and development expense rose to $505.9 million from $353.2 million. The company said its recent Sarepta licensing deal and Sixth Street credit facility, both announced in the filing period, extend its cash runway into 2028.
Revenue was $3.6 million in fiscal 2024 versus $240.7 million in fiscal 2023.
Diluted net loss per share was $5.00 versus $1.92 a year earlier.
Research and development expense was $505.9 million versus $353.2 million.
Sarepta agreement provides $825 million upon closing, including a $325 million equity investment; Sixth Street facility is $500 million, with $400 million funded at close.
Abercrombie & Fitch appointed Robert Ball as Senior Vice President and Chief Financial Officer, effective November 20, 2024, replacing Scott Lipesky, who remains Executive Vice President and Chief Operating Officer. The board also adopted amendments to the company's bylaws on stockholder proposals, nominations and share issuance, effective the same date.
Robert Ball, who joined the company in 2003, was appointed CFO effective November 20, 2024, with an annual base salary of $500,000 and a 60% target incentive opportunity starting in fiscal 2025.
Scott Lipesky ceased to be CFO and principal accounting officer as of November 20, 2024, and will continue as Executive Vice President and Chief Operating Officer.
Joseph Frericks was named principal accounting officer, effective November 20, 2024.
Bylaw amendments add a rule that stockholders soliciting proxies must use a color other than white for their proxy card, and revise advance notice requirements for proposals and director nominations.
For the quarter ended October 31, 2024, J.M. Smucker reported net sales of $2.3 billion, up 17% mainly due to the Hostess Brands acquisition, and adjusted earnings per share of $2.76, up 7%. The company posted a GAAP net loss of $0.23 per diluted share, versus earnings of $1.90 a year earlier, after a $260.8 million pre-tax loss on the Voortman business held for sale. The company raised its full-year fiscal 2025 adjusted earnings per share guidance to $9.70 to $10.10 from $9.60 to $10.00.
Net sales were $2.3 billion, up $332.6 million or 17%; excluding the acquisition, divestitures, and currency, net sales rose 2%.
GAAP net loss of $0.23 per diluted share, compared with $1.90 a year earlier, including a $260.8 million pre-tax loss on the Voortman business.
Adjusted earnings per share were $2.76, up 7%; free cash flow was $317.2 million versus $28.2 million a year earlier.
Fiscal 2025 adjusted earnings per share guidance raised to $9.70 to $10.10 from $9.60 to $10.00; net sales growth guidance unchanged at 8.5% to 9.5%.
DICK'S Sporting Goods reported third-quarter net sales of $3.06 billion, up 0.5%, and diluted earnings per share of $2.75, up from $2.39 a year earlier. Comparable sales rose 4.2%. The company raised its full-year 2024 guidance for diluted EPS to $13.65 to $13.95 from $13.55 to $13.90, and for comparable sales growth to 3.6% to 4.2% from 2.5% to 3.5%.
Q3 net sales $3.06 billion, up 0.5%; the calendar shift reduced sales by about $105 million
Q3 diluted EPS $2.75 vs. $2.39 a year earlier; non-GAAP EPS was $2.75 vs. $2.85
Full-year 2024 diluted EPS guidance raised to $13.65 to $13.95; comparable sales guidance raised to 3.6% to 4.2%
Board declared a quarterly dividend of $1.10 per share, payable December 27, 2024, to holders of record on December 13, 2024
Best Buy reported third-quarter fiscal 2025 revenue of $9.45 billion, down from $9.76 billion a year earlier, with enterprise comparable sales down 2.9%. GAAP diluted EPS rose to $1.26 from $1.21, while non-GAAP diluted EPS fell to $1.26 from $1.29. The company lowered its full-year comparable sales and revenue guidance, which matters to shareholders because it signals weaker expected demand for the year.
Q3 revenue was $9,445 million versus $9,756 million a year earlier; enterprise comparable sales declined 2.9%.
GAAP diluted EPS was $1.26 versus $1.21; non-GAAP diluted EPS was $1.26 versus $1.29.
FY25 comparable sales guidance was cut to a decline of 2.5% to 3.5% from a decline of 1.5% to 3.0%; revenue guidance is now $41.1 billion to $41.5 billion versus $41.3 billion to $41.9 billion.
Board authorized a regular quarterly cash dividend of $0.94 per share, payable January 7, 2025, to holders of record on December 17, 2024.
Burlington reported third-quarter fiscal 2024 total sales up 11% to $2,526 million and net income of $91 million, or $1.40 per diluted share, versus $49 million, or $0.75, a year earlier. The company raised its full-year fiscal 2024 adjusted EPS guidance to $7.76 to $7.96, but comparable store sales grew only 1%, and its fourth-quarter guidance calls for a lower adjusted EBIT margin.
Q3 total sales rose 11% to $2,526 million; comparable store sales rose 1%, which management attributed to warmer weather from mid-September.
Q3 net income was $91 million, or $1.40 per diluted share; adjusted EPS rose 41% to $1.55.
Full-year fiscal 2024 adjusted EPS guidance was raised to $7.76 to $7.96.
Fourth-quarter guidance calls for comparable store sales growth of 0% to 2% and an adjusted EBIT margin decline of 50 to 80 basis points.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.